Načítá se...
Cellular immunotherapy for refractory DLBCL in the CART era: still a role for allogeneic transplantation?
Chimeric antigen receptor-engineered T (CART) cells are a promising new treatment option for patients with multiply relapsed and refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Because of the favourable outcome data reported for CART cells, uncertainty is emerging if there is still a role fo...
Uloženo v:
| Vydáno v: | Biol Blood Marrow Transplant |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7207150/ https://ncbi.nlm.nih.gov/pubmed/31917272 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2019.12.771 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|